Pfizer

PFE

Market cap $157B

Pfizer is facing patent cliffs on multiple drugs in the next few years. The company has been making big acquisitions to strengthen its growth prospects.

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February.

Pfizer is building a robust mid- and late-stage pipeline, positioning for a return to growth later this decade that is not reflected in the current analyst consensus. Recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight incremental but meaningful pipeline progress. The obesity pipeline, led by PF'3944, is advancing rapidly with 10 phase 3 trials, and the company has recently shared promising phase 2 results that showed the feasibility of monthly dosing.

Dan Deming is impressed with the sharp stock market rally to all-time highs, though he urges caution for a potential stall in the price action. For today's Big 3, he sees Pfizer's (PFE) support making a case for a buying opportunity, Visa (V) forming a bottom, and Synchrony Financial (SYF) as a volatile stock heading into earnings.

When researching pharma companies, investors might start by reviewing the drug pipeline. Companies constantly need to be developing their next flagship drug.

Pfizer  PFE is scheduled to report its first-quarter 2026 results on May 5, with investor focus firmly on its oncology portfolio, which contributes roughly 27% of total revenues. Leading cancer therapies in its lineup include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates like Padcev acquired through Seagen.

Investing in high-yielding dividend stocks can be risky, but the ones on this list can be gems. These stocks yield between 6.2% and 6.4%.

Two million dollars in four household-name dividend payers can generate between $132,000 and $146,000 in annual income.

A million dollars sounds like enough to retire on. Whether it actually is depends entirely on what you make it do.

Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.